BRTX · BioRestorative Therapies, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Based on these conditions, we believe we do not have sufficient cash for at least twelve months after the issuance date of the financial statements included in this Quarterly Report which raises substantial doubt about our ability to continue as a going concern.”View the 10-Q filed May 14, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Oct 27, 2021; bars on opposite sides are not compared.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BRTX
this stock
BioRestorative Therapies, Inc.
|
$5.49M | -81.7% | +122.8% | — | 1.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.91B | +20.9% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.87B | +8.1% | +20.8% | 20.7 | 3.3% |
|
ARGX
Argenx SE
|
$64.66B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$57.97B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Oct 27, 2021; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BRTX | -4.7% | -25.8% | +0.7% | +5.2% | -81.7% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | -3.3% | -29.4% | -10.9% | +2.7% | -94.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.